Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Остеоартроз в практике невролога: старые-новые возможности
Остеоартроз в практике невролога: старые-новые возможности
Путилина М.В. Остеоартроз в практике невролога: старые-новые возможности. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 1: 66–68.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Остеоартроз (ОА) – гетерогенная группа заболеваний, различных по клинической картине и исходам, в основе которых лежит поражение всех составляющих элементов сустава. В неврологических рекомендациях проблема ОА практически не рассматривалась, за исключением аспектов хронической боли, поэтому использование препаратов, максимально безопасных и эффективных у разных пациентов, рассматривается с позиций терапевтических и ревматологических критериев. Комитет Европейского общества по клиническим и экономическим аспектам остеопороза и остеоартрита (ESCEO – European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) в 2014 г. предложил алгоритм ведения больных ОА в реальной клинической практике. Согласно этому документу в качестве базисной терапии рекомендуется назначение хондроитина сульфата и глюкозамина или их комбинации с короткими курсами назначения парацетамола для быстрого обезболивающего эффекта.
Ключевые слова: остеоартроз, боль в спине, хондропротекторы.
Key words: osteoarthritis, back pain, chondroprotectors.
Ключевые слова: остеоартроз, боль в спине, хондропротекторы.
________________________________________________
Key words: osteoarthritis, back pain, chondroprotectors.
Полный текст
Список литературы
1. Алексеева Л.И., Шарапова Е.П., Кашеварова Н.Г. и др. Применение Артра® MСM Форте у пациентов с остеоартрозом коленного сустава: результаты рандомизированного открытого сравнительного изучения эффективности и переносимости препарата. Справ. поликлин. врача. 2015; 8: 24–7. / Alekseeva L.I., Sharapova E.P., Kashevarova N.G. i dr. Primenenie Artra® MSM Forte u patsientov s osteoartrozom kolennogo sustava: rezul'taty randomizirovannogo otkrytogo sravnitel'nogo izucheniia effektivnosti i perenosimosti preparata. Sprav. poliklin. vracha. 2015; 8: 24–7. [in Russian]
2. Manek NJ, MacGregor AJ. Epidemiology of Back Disorders: prevalence, risk factors, and prognosis. Сurr Opin Rheumatol 2005; 17 (2): 134–40.
3. Fardon DF, Milette PC. Nomenclature and classification of lumbar disk pathology: recommendations of the combined task forces of the North Am Spine Soc, Am Soc Spine Radiol, Am Soc Neuroradiol. Spine 2001; 26: 93–113.
4. Шостак Н.А. Дорсопатии – совершенствование терапевтических возможностей. Трудный пациент. 2006; 10: 24–30. / Shostak N.A. Dorsopatii – sovershenstvovanie terapevticheskikh vozmozhnostei. Trudnyi patsient. 2006; 10: 24–30. [in Russian]
5. McAlindon T, Bannuru R, Sullivan M et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. Doi:10.1016/j.joca.2015.02.014.
6. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78: 184–7. Doi:10.1016/j.maturitas.2014.07.018.
7. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008; 47 (6): 809–14.
8. Martin MD, Boxell CM, Malone DG. Pathophysiology of Lumbar Disc Degeneration: A Review of the Literature. Neurosurgical Focus 2002; 13 (2). www.medscape.com/viewarticle/442440
9. Hochberg M, Martel-Pelletier J, Monfort J et al. The Multicentric Osteoarthritis interVEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage 2014; 22: S7–S56. Doi: 10.1136/annrheumdis-2014-eular.4950.
10. Fransen M, Agaliotis M, Nairn L et al. Glucosamine and chondroitin for knee placebo-controlled clinical trial evaluating osteoarthritis: a double-blind randomised single and combination regimens. Ann Rheum Dis 2015; 74 (5): 851–8. Doi:10.1136/annrheumdis-2013-203954.
11. Bruyère O, Cooper C, Pelletier J et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; p. 2–11. Doi:10.1016/j.semarthrit.2014.05.014.
12. Blitterswijk WJ, Jos CM, Van de Nes, Wuisman P. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: Biochemical rationale and case report. BMC Complement Altern Med 2003; 3: 2.
13. Алексеева Л.И., Чичасова Н.В., Мендель О.И. и др. Рациональный выбор базисной терапии при остеоартрозе. Результаты открытого рандомизированного многоцентрового исследования препарата Артра в России. РМЖ. 2005; 13 (24): 1637–40. / Alekseeva L.I., Chichasova N.V., Mendel' O.I. i dr. Ratsional'nyi vybor bazisnoi terapii pri osteoartroze. Rezul'taty otkrytogo randomizirovannogo mnogotsentrovogo issledovaniia preparata Artra v Rossii. RMZh. 2005; 13 (24): 1637–40. [in Russian]
14. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
15. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003; 23: 453–8.
16. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann NY Acad Sci 1983; 411: 318–20. Doi: 10.1111/j.1749-6632.1983.tb47314.x.
17. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987; 110: 91–6.
18. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
19. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004; 24: 353–63. Doi: 10.2165/00044011-200424060-00005.
20. Kim LS, Axelrod LJ, Howard P et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis Cartilage 2006; 14: 286–94. Doi:10.1016/j.joca.2005.10.003.
21. Pagonis TA, Givissis PK, Kritis AC, Christodoulou AC. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J Orthopaedics 2014; 1 (1): 19–24. Doi: http://dx.doi.org/10.1016/j.injury.2011.03.018.
22. Vidyasagar S, Mukhyaprana P, Shashikiran U et al. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate – Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Int J Pharmacy Technol 2004; 3: 61–5.
2. Manek NJ, MacGregor AJ. Epidemiology of Back Disorders: prevalence, risk factors, and prognosis. Сurr Opin Rheumatol 2005; 17 (2): 134–40.
3. Fardon DF, Milette PC. Nomenclature and classification of lumbar disk pathology: recommendations of the combined task forces of the North Am Spine Soc, Am Soc Spine Radiol, Am Soc Neuroradiol. Spine 2001; 26: 93–113.
4. Shostak N.A. Dorsopatii – sovershenstvovanie terapevticheskikh vozmozhnostei. Trudnyi patsient. 2006; 10: 24–30. [in Russian]
5. McAlindon T, Bannuru R, Sullivan M et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. Doi:10.1016/j.joca.2015.02.014.
6. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78: 184–7. Doi:10.1016/j.maturitas.2014.07.018.
7. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008; 47 (6): 809–14.
8. Martin MD, Boxell CM, Malone DG. Pathophysiology of Lumbar Disc Degeneration: A Review of the Literature. Neurosurgical Focus 2002; 13 (2). www.medscape.com/viewarticle/442440
9. Hochberg M, Martel-Pelletier J, Monfort J et al. The Multicentric Osteoarthritis interVEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage 2014; 22: S7–S56. Doi: 10.1136/annrheumdis-2014-eular.4950.
10. Fransen M, Agaliotis M, Nairn L et al. Glucosamine and chondroitin for knee placebo-controlled clinical trial evaluating osteoarthritis: a double-blind randomised single and combination regimens. Ann Rheum Dis 2015; 74 (5): 851–8. Doi:10.1136/annrheumdis-2013-203954.
11. Bruyère O, Cooper C, Pelletier J et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; p. 2–11. Doi:10.1016/j.semarthrit.2014.05.014.
12. Blitterswijk WJ, Jos CM, Van de Nes, Wuisman P. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: Biochemical rationale and case report. BMC Complement Altern Med 2003; 3: 2.
13. Alekseeva L.I., Chichasova N.V., Mendel' O.I. i dr. Ratsional'nyi vybor bazisnoi terapii pri osteoartroze. Rezul'taty otkrytogo randomizirovannogo mnogotsentrovogo issledovaniia preparata Artra v Rossii. RMZh. 2005; 13 (24): 1637–40. [in Russian]
14. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
15. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003; 23: 453–8.
16. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann NY Acad Sci 1983; 411: 318–20. Doi: 10.1111/j.1749-6632.1983.tb47314.x.
17. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987; 110: 91–6.
18. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
19. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004; 24: 353–63. Doi: 10.2165/00044011-200424060-00005.
20. Kim LS, Axelrod LJ, Howard P et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis Cartilage 2006; 14: 286–94. Doi:10.1016/j.joca.2005.10.003.
21. Pagonis TA, Givissis PK, Kritis AC, Christodoulou AC. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J Orthopaedics 2014; 1 (1): 19–24. Doi: http://dx.doi.org/10.1016/j.injury.2011.03.018.
22. Vidyasagar S, Mukhyaprana P, Shashikiran U et al. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate – Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Int J Pharmacy Technol 2004; 3: 61–5.
2. Manek NJ, MacGregor AJ. Epidemiology of Back Disorders: prevalence, risk factors, and prognosis. Сurr Opin Rheumatol 2005; 17 (2): 134–40.
3. Fardon DF, Milette PC. Nomenclature and classification of lumbar disk pathology: recommendations of the combined task forces of the North Am Spine Soc, Am Soc Spine Radiol, Am Soc Neuroradiol. Spine 2001; 26: 93–113.
4. Шостак Н.А. Дорсопатии – совершенствование терапевтических возможностей. Трудный пациент. 2006; 10: 24–30. / Shostak N.A. Dorsopatii – sovershenstvovanie terapevticheskikh vozmozhnostei. Trudnyi patsient. 2006; 10: 24–30. [in Russian]
5. McAlindon T, Bannuru R, Sullivan M et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. Doi:10.1016/j.joca.2015.02.014.
6. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78: 184–7. Doi:10.1016/j.maturitas.2014.07.018.
7. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008; 47 (6): 809–14.
8. Martin MD, Boxell CM, Malone DG. Pathophysiology of Lumbar Disc Degeneration: A Review of the Literature. Neurosurgical Focus 2002; 13 (2). www.medscape.com/viewarticle/442440
9. Hochberg M, Martel-Pelletier J, Monfort J et al. The Multicentric Osteoarthritis interVEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage 2014; 22: S7–S56. Doi: 10.1136/annrheumdis-2014-eular.4950.
10. Fransen M, Agaliotis M, Nairn L et al. Glucosamine and chondroitin for knee placebo-controlled clinical trial evaluating osteoarthritis: a double-blind randomised single and combination regimens. Ann Rheum Dis 2015; 74 (5): 851–8. Doi:10.1136/annrheumdis-2013-203954.
11. Bruyère O, Cooper C, Pelletier J et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; p. 2–11. Doi:10.1016/j.semarthrit.2014.05.014.
12. Blitterswijk WJ, Jos CM, Van de Nes, Wuisman P. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: Biochemical rationale and case report. BMC Complement Altern Med 2003; 3: 2.
13. Алексеева Л.И., Чичасова Н.В., Мендель О.И. и др. Рациональный выбор базисной терапии при остеоартрозе. Результаты открытого рандомизированного многоцентрового исследования препарата Артра в России. РМЖ. 2005; 13 (24): 1637–40. / Alekseeva L.I., Chichasova N.V., Mendel' O.I. i dr. Ratsional'nyi vybor bazisnoi terapii pri osteoartroze. Rezul'taty otkrytogo randomizirovannogo mnogotsentrovogo issledovaniia preparata Artra v Rossii. RMZh. 2005; 13 (24): 1637–40. [in Russian]
14. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
15. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003; 23: 453–8.
16. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann NY Acad Sci 1983; 411: 318–20. Doi: 10.1111/j.1749-6632.1983.tb47314.x.
17. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987; 110: 91–6.
18. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
19. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004; 24: 353–63. Doi: 10.2165/00044011-200424060-00005.
20. Kim LS, Axelrod LJ, Howard P et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis Cartilage 2006; 14: 286–94. Doi:10.1016/j.joca.2005.10.003.
21. Pagonis TA, Givissis PK, Kritis AC, Christodoulou AC. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J Orthopaedics 2014; 1 (1): 19–24. Doi: http://dx.doi.org/10.1016/j.injury.2011.03.018.
22. Vidyasagar S, Mukhyaprana P, Shashikiran U et al. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate – Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Int J Pharmacy Technol 2004; 3: 61–5.
________________________________________________
2. Manek NJ, MacGregor AJ. Epidemiology of Back Disorders: prevalence, risk factors, and prognosis. Сurr Opin Rheumatol 2005; 17 (2): 134–40.
3. Fardon DF, Milette PC. Nomenclature and classification of lumbar disk pathology: recommendations of the combined task forces of the North Am Spine Soc, Am Soc Spine Radiol, Am Soc Neuroradiol. Spine 2001; 26: 93–113.
4. Shostak N.A. Dorsopatii – sovershenstvovanie terapevticheskikh vozmozhnostei. Trudnyi patsient. 2006; 10: 24–30. [in Russian]
5. McAlindon T, Bannuru R, Sullivan M et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22 (3): 363–88. Doi:10.1016/j.joca.2015.02.014.
6. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas 2014; 78: 184–7. Doi:10.1016/j.maturitas.2014.07.018.
7. Hoyland JA, Le Maitre C, Freemont AJ. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008; 47 (6): 809–14.
8. Martin MD, Boxell CM, Malone DG. Pathophysiology of Lumbar Disc Degeneration: A Review of the Literature. Neurosurgical Focus 2002; 13 (2). www.medscape.com/viewarticle/442440
9. Hochberg M, Martel-Pelletier J, Monfort J et al. The Multicentric Osteoarthritis interVEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage 2014; 22: S7–S56. Doi: 10.1136/annrheumdis-2014-eular.4950.
10. Fransen M, Agaliotis M, Nairn L et al. Glucosamine and chondroitin for knee placebo-controlled clinical trial evaluating osteoarthritis: a double-blind randomised single and combination regimens. Ann Rheum Dis 2015; 74 (5): 851–8. Doi:10.1136/annrheumdis-2013-203954.
11. Bruyère O, Cooper C, Pelletier J et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars Arthritis Rheum 2014; p. 2–11. Doi:10.1016/j.semarthrit.2014.05.014.
12. Blitterswijk WJ, Jos CM, Van de Nes, Wuisman P. Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: Biochemical rationale and case report. BMC Complement Altern Med 2003; 3: 2.
13. Alekseeva L.I., Chichasova N.V., Mendel' O.I. i dr. Ratsional'nyi vybor bazisnoi terapii pri osteoartroze. Rezul'taty otkrytogo randomizirovannogo mnogotsentrovogo issledovaniia preparata Artra v Rossii. RMZh. 2005; 13 (24): 1637–40. [in Russian]
14. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
15. Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention. Anticancer Res 2003; 23: 453–8.
16. Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells. Ann NY Acad Sci 1983; 411: 318–20. Doi: 10.1111/j.1749-6632.1983.tb47314.x.
17. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. J Lab Clin Med 1987; 110: 91–6.
18. Hasegawa T. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japan Pharmacol Ther 2004; 32: 421–7.
19. Usha P, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004; 24: 353–63. Doi: 10.2165/00044011-200424060-00005.
20. Kim LS, Axelrod LJ, Howard P et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. OsteoArthritis Cartilage 2006; 14: 286–94. Doi:10.1016/j.joca.2005.10.003.
21. Pagonis TA, Givissis PK, Kritis AC, Christodoulou AC. The Effect of Methylsulfonylmethane on Osteoarthritic Large Joints and Mobility. Int J Orthopaedics 2014; 1 (1): 19–24. Doi: http://dx.doi.org/10.1016/j.injury.2011.03.018.
22. Vidyasagar S, Mukhyaprana P, Shashikiran U et al. Efficacy and Tolerability of Glucosamine Chondroitin Sulphate – Methyl Sulfonyl Methane (MSM) in Osteoarthritis of Knee in Indian Patients. Int J Pharmacy Technol 2004; 3: 61–5.
Авторы
М.В.Путилина*
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*profput@mail.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*profput@mail.ru
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*profput@mail.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*profput@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.